The relationship between serum human immunodeficiency virus type 1 (HIV- 1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1- infected children

Journal of Infectious Diseases

Volumn 175, Issue 5, 1997, Pages 1029-1038

  Mofenson, Lynne M ^a   Korelitz, James ^b   Meyer III, William A ^b   Bethel, James ^b   Rich, Kenneth ^b   Pahwa, Savita ^b   Moye Jr , John ^b   Nugent, Robert ^b   Read, Jennifer ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN; VIRUS RNA;

ARTICLE; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030962564     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516441     Document Type: Article

References (24)

1. Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996;10:167-73.
2. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.
3. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996;124:984-94.
4. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
5. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
6. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4 lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
7. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-9.
8. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
9. Palumbo PE, Kwok S, Waters S, et al. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr 1995;126:592-5.
10. McIntosh K, Shevitz A, Zaknun D, et al. Age- and time-related changes in extracellular viral load in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1996;15:1087-91.
11. Abrams EJ, Weedon JC, Lambert G, Steketee R. HIV viral load early in life as a predictor of disease progression in infected infants [abstract We.B.311]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: WorldPower Business Services, 1996:25.
12. Shearer WT, Quinn T, La Russa P, et al. Prospective evaluation of plasma HIV-1 RNA copy number in 106 HIV-infected children from the Women and Infants Transmission Study [abstract Th.B.910]. In: Program and abstracts: XI International Conference on AIDS (Vancouver, Canada). Vancouver: WorldPower Business Services, 1996:16.
13. De Rossi A, Masiero S, Giaquinto C, et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996;97:323-30.
14. National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;325:73-80.
15. 9/L or more: effect on viral, opportunistic, and bacterial infections. JAMA 1992;268:483-8.
16. + lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. J Acquir Immune Defic Syndr 1993;6:1103-13.
17. Mofenson LM, Moye J, Korelitz J, et al. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994;13:477-84.
18. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantitative methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1995;170:553-62.
19. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-10.
20. Clementi M, Menzo S, Bagnarelli P, et al. Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clin Microbiol Rev 1996;9:135-47.
21. Jurriaans S, van Gemen B, Weverling GJ, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994;204:223-33.
22. Ioannidis JPA, Cappelleri JC, Lau J, Sacks HS, Skolnik PR. Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model. AIDS 1996;10:255-62.
23. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
24. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 1996;276:105-10.